Developer docs
API playgroundTry for free, no card

Search company profiles

Endovascular Engineering

Full company profile

uuid0000e79

Namestring
Endovascular Engineering
Legal namestring
Endovascular Engineering, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Endovascular Engineering, Inc. (E2) is a private medical device company headquartered in Menlo Park, California, that develops mechanical thrombectomy systems for the treatment of venous thromboembolism (VTE). Founded in 2019 and operating with 11–50 employees, the company targets hospital-based interventional cardiology and radiology departments performing procedures for pulmonary embolism (PE) and deep vein thrombosis (DVT). E2 has raised $137 million across three funding rounds (Series A1 in 2022, Series B in early 2025, and an oversubscribed Series C in April 2026) from a syndicate including Gilde Healthcare, Norwest, Santé Ventures, Cordis, S3 Ventures, 415 Capital, Panakès Partners, and M&L Healthcare Investments.

The company's sole commercial product is the Hēlo™ Thrombectomy System, which received FDA 510(k) clearance in late 2025 for clot removal from pulmonary arteries and peripheral veins. The device is built around a patented dual-action mechanism that combines high-speed mechanical agitation with physician-controlled simultaneous aspiration, delivered through a small-profile catheter that houses a self-expanding funnel. This architecture is designed to give operators the navigational agility of a small-bore catheter while matching the clot-engagement performance of large-bore devices, enabling single-pass clot removal in complex anatomies with reduced hemodynamic impact. Clinical evidence is anchored by the ENGULF IDE program (feasibility n=25 plus pivotal cohort), with feasibility data published in JSCAI and pivotal results presented at SIR, SCAI, and VIVA conferences.

E2 generates revenue through direct hardware sales of the Hēlo system to U.S. hospitals, with pricing negotiated through hospital procurement and group purchasing organizations. The company employs an enterprise field sales motion, having recently built out dedicated SVP of Sales, VP of Marketing, and SVP Clinical and Market Development functions to drive adoption at target accounts. As a newly commercial-stage device company, E2 is investing heavily in scaling its commercial organization, funded by the April 2026 Series C. The company is led by CEO Dan Rose, with Founder Luis Savastano, MD, PhD serving as Chief Scientific Officer.

Short descriptiontext

Endovascular Engineering develops and commercializes the FDA-cleared Hēlo Thrombectomy System, a catheter-based mechanical thrombectomy device for treating pulmonary embolism and deep vein thrombosis in hospital interventional cardiology and radiology departments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mechanical thrombectomy catheters, venous thromboembolism treatment, pulmonary embolism devices, endovascular medical devices, clot removal systems
Industry1 code
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Interventional Cardiology & Vascular Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Hēlo Thrombectomy System (Hardware Sales)
TypeHardware Sales
Description

E2 generates revenue from the sale of its FDA-cleared Hēlo Thrombectomy System to hospital interventional cardiology and radiology departments. As a commercial-stage medical device company, revenue is derived from direct product sales to healthcare providers for use in pulmonary embolism and venous thrombectomy procedures.

medtechdive.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Endovascular Engineering develops and commercializes the Hēlo™ Thrombectomy System, an FDA-cleared mechanical thrombectomy catheter for the treatment of venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis. The catheter-based system combines aspiration with mechanical clot disruption via a self-expanding funnel design, enabling small-profile navigation with large-bore clot engagement in a single-pass procedure.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Feasibility study demonstrated safety and feasibility in 25 intermediate-risk PE patients
+1 more record
Product overview1 text field

Endovascular Engineering offers a single unified product—the Hēlo™ Thrombectomy System (also referred to as the Hēlo® Thrombectomy Platform or Hēlo® PE Thrombectomy System). This is a medical device platform designed for mechanical thrombectomy treatment of venous thromboembolism (VTE), specifically targeting pulmonary embolism (PE) and deep vein thrombosis (DVT). The system features a patented dual-action mechanism combining aspiration with mechanical clot disruption, housed in a small-profile catheter with a self-expanding funnel that expands for effective large bore clot engagement. The device received FDA 510(k) clearance in late 2025 and is now in commercial stage.

Product and service1 record
1Hēlo™ PE Thrombectomy System
CategoryMechanical Thrombectomy Catheter System
Description

A next-generation mechanical thrombectomy catheter system for treating venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis. Features a self-expanding funnel design and dual-action technology combining high-speed agitation with physician-controlled aspiration for single-pass clot removal, intended for use by interventional cardiologists and radiologists in hospital settings.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Eric Secemsky, MD, MSc
Strategic tierMinorTypeOthers
Description

Director of Cardiovascular Catheterization Laboratories at the Hospital of the University of Pennsylvania. Listed as a Key Clinical Partner on the company About page, providing clinical advisory and validation for the Hēlo platform.

endovascularengineering.com
2Jay Giri, MD, MPH
Strategic tierMinorTypeOthers
Description

National Principal Investigator for the ENGULF feasibility study. Listed as a Key Clinical Partner on the company About page. Published clinical data supporting the Hēlo system in peer-reviewed literature.

endovascularengineering.com
3Andrew Klein, MD
Strategic tierMinorTypeOthers
Description

National co-Principal Investigator for the ENGULF pivotal study. Listed as a Key Clinical Partner on the company About page.

endovascularengineering.com
4Julie Bulman, MD
Strategic tierMinorTypeOthers
Description

National co-Principal Investigator for the ENGULF pivotal study. Listed as a Key Clinical Partner on the company About page.

endovascularengineering.com
5Kush Desai, MD
Strategic tierMinorTypeOthers
Description

Listed as a Key Clinical Partner on the company About page, providing clinical expertise in interventional radiology for the Hēlo platform.

endovascularengineering.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Inari Medical (acquired by Stryker for $4.9B in 2025) developed the FlowTriever system for mechanical thrombectomy in PE and DVT. It is the direct competitor to Endovascular Engineering's Hēlo system, targeting the same interventional cardiology and radiology call points with similar catheter-based clot removal technology.

TypeDirect peer
Description

Penumbra's Indigo and Lightning systems are leading mechanical thrombectomy platforms for PE and peripheral clot removal. It is a direct competitor to Hēlo with a large installed base, established clinical data, and a global hospital sales force.

TypeDirect peer
Description

AngioDynamics markets the AlphaVac mechanical thrombectomy system for PE treatment and is the plaintiff in the active patent infringement suit against Endovascular Engineering. It competes head-to-head with Hēlo in the PE thrombectomy category.

TypeBroad incumbent
Description

Boston Scientific offers the EKOS ultrasound-assisted thrombolysis system for PE and DVT through its peripheral interventions franchise. It is a broad incumbent in interventional cardiology/radiology with the scale and channel access to compete against Hēlo.

TypeBroad incumbent
Description

Stryker acquired Inari Medical for $4.9B and now owns the FlowTriever platform, making it the dominant player in mechanical thrombectomy. Stryker's Neurovascular division also competes in adjacent stroke intervention devices, giving it a broad incumbency over the thrombectomy space.

TypeBroad incumbent
Description

Cerenovus, J&J's neurovascular and thrombectomy business, offers stent retriever and aspiration technologies for clot removal. It is a broad incumbent with overlapping capabilities in mechanical thrombectomy across peripheral and neurovascular indications.

TypeBroad incumbent
Description

Medtronic's peripheral vascular and cardiac franchises include catheter-based technologies that overlap with Hēlo's addressable market. Its scale, hospital relationships, and ability to bundle across indications make it a powerful indirect competitor and potential acquirer.

8Abbott
TypeBroad incumbent
Description

Abbott's vascular and structural heart businesses include catheter-based technologies and would be a relevant broad incumbent comparable in scale and channel access for any thrombectomy platform reaching commercial scale.

TypeEmerging player
Description

Walk Vascular develops the JETi mechanical thrombectomy system for peripheral and venous applications. It is an emerging niche player with meaningful but partial overlap to Hēlo in the mechanical thrombectomy category.

TypeEmerging player
Description

Surmodics has developed catheter-based thrombectomy and drug-delivery coating technologies serving peripheral vascular markets. It is an emerging player with adjacent technology overlap relevant to Endovascular Engineering's catheter platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Endovascular Engineering

Interventional Cardiology & Vascular Medical Devicesendovascularengineering.com

Endovascular Engineering develops and commercializes the FDA-cleared Hēlo Thrombectomy System, a catheter-based mechanical thrombectomy device for treating pulmonary embolism and deep vein thrombosis in hospital interventional cardiology and radiology departments.

What Endovascular Engineering does

Endovascular Engineering, Inc. (E2) is a private medical device company headquartered in Menlo Park, California, that develops mechanical thrombectomy systems for the treatment of venous thromboembolism (VTE). Founded in 2019 and operating with 11–50 employees, the company targets hospital-based interventional cardiology and radiology departments performing procedures for pulmonary embolism (PE) and deep vein thrombosis (DVT). E2 has raised $137 million across three funding rounds (Series A1 in 2022, Series B in early 2025, and an oversubscribed Series C in April 2026) from a syndicate including Gilde Healthcare, Norwest, Santé Ventures, Cordis, S3 Ventures, 415 Capital, Panakès Partners, and M&L Healthcare Investments.

The company's sole commercial product is the Hēlo™ Thrombectomy System, which received FDA 510(k) clearance in late 2025 for clot removal from pulmonary arteries and peripheral veins. The device is built around a patented dual-action mechanism that combines high-speed mechanical agitation with physician-controlled simultaneous aspiration, delivered through a small-profile catheter that houses a self-expanding funnel. This architecture is designed to give operators the navigational agility of a small-bore catheter while matching the clot-engagement performance of large-bore devices, enabling single-pass clot removal in complex anatomies with reduced hemodynamic impact. Clinical evidence is anchored by the ENGULF IDE program (feasibility n=25 plus pivotal cohort), with feasibility data published in JSCAI and pivotal results presented at SIR, SCAI, and VIVA conferences.

E2 generates revenue through direct hardware sales of the Hēlo system to U.S. hospitals, with pricing negotiated through hospital procurement and group purchasing organizations. The company employs an enterprise field sales motion, having recently built out dedicated SVP of Sales, VP of Marketing, and SVP Clinical and Market Development functions to drive adoption at target accounts. As a newly commercial-stage device company, E2 is investing heavily in scaling its commercial organization, funded by the April 2026 Series C. The company is led by CEO Dan Rose, with Founder Luis Savastano, MD, PhD serving as Chief Scientific Officer.

Endovascular Engineering firmographics

Firmographics
Name
Endovascular Engineering
Legal name
Endovascular Engineering, Inc.
Website
https://endovascularengineering.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Endovascular Engineering develops and commercializes the FDA-cleared Hēlo Thrombectomy System, a catheter-based mechanical thrombectomy device for treating pulmonary embolism and deep vein thrombosis in hospital interventional cardiology and radiology departments.
Ownership category
akta.pro rank

Endovascular Engineering industry classification

Industry
Product category
Interventional Cardiology & Vascular Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Mechanical thrombectomy catheters
  • Venous thromboembolism treatment
  • Pulmonary embolism devices
  • Endovascular medical devices
  • Clot removal systems

Where Endovascular Engineering is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Endovascular Engineering business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

  1. Hēlo Thrombectomy System (Hardware Sales): E2 generates revenue from the sale of its FDA-cleared Hēlo Thrombectomy System to hospital interventional cardiology and radiology departments. As a commercial-stage medical device company, revenue is derived from direct product sales to healthcare providers for use in pulmonary embolism and venous thrombectomy procedures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Endovascular Engineering product offering

Product offering

Core offering

Endovascular Engineering develops and commercializes the Hēlo™ Thrombectomy System, an FDA-cleared mechanical thrombectomy catheter for the treatment of venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis. The catheter-based system combines aspiration with mechanical clot disruption via a self-expanding funnel design, enabling small-profile navigation with large-bore clot engagement in a single-pass procedure.

Product overview

Endovascular Engineering offers a single unified product—the Hēlo™ Thrombectomy System (also referred to as the Hēlo® Thrombectomy Platform or Hēlo® PE Thrombectomy System). This is a medical device platform designed for mechanical thrombectomy treatment of venous thromboembolism (VTE), specifically targeting pulmonary embolism (PE) and deep vein thrombosis (DVT). The system features a patented dual-action mechanism combining aspiration with mechanical clot disruption, housed in a small-profile catheter with a self-expanding funnel that expands for effective large bore clot engagement. The device received FDA 510(k) clearance in late 2025 and is now in commercial stage.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hēlo™ PE Thrombectomy System A next-generation mechanical thrombectomy catheter system for treating venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis. Features a self-expanding funnel design and dual-action technology combining high-speed agitation with physician-controlled aspiration for single-pass clot removal, intended for use by interventional cardiologists and radiologists in hospital settings.

Quantifiable outcome

  • Feasibility study demonstrated safety and feasibility in 25 intermediate-risk PE patients
  • +1 more outcomes

Companies that use Endovascular Engineering

Customer profile

Segments1 record

Ideal customer profiles1 record

Endovascular Engineering technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Endovascular Engineering partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor.

  • Eric Secemsky, MD, MScminorOthersDirector of Cardiovascular Catheterization Laboratories at the Hospital of the University of Pennsylvania. Listed as a Key Clinical Partner on the company About page, providing clinical advisory and validation for the Hēlo platform.
  • Jay Giri, MD, MPHminorOthersNational Principal Investigator for the ENGULF feasibility study. Listed as a Key Clinical Partner on the company About page. Published clinical data supporting the Hēlo system in peer-reviewed literature.
  • Andrew Klein, MDminorOthersNational co-Principal Investigator for the ENGULF pivotal study. Listed as a Key Clinical Partner on the company About page.
  • Julie Bulman, MDminorOthersNational co-Principal Investigator for the ENGULF pivotal study. Listed as a Key Clinical Partner on the company About page.
  • Kush Desai, MDminorOthersListed as a Key Clinical Partner on the company About page, providing clinical expertise in interventional radiology for the Hēlo platform.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Endovascular Engineering competitors and assessment

Company assessment

Direct peers

  • Inari Medical: Inari Medical (acquired by Stryker for $4.9B in 2025) developed the FlowTriever system for mechanical thrombectomy in PE and DVT. It is the direct competitor to Endovascular Engineering's Hēlo system, targeting the same interventional cardiology and radiology call points with similar catheter-based clot removal technology.
  • Penumbra: Penumbra's Indigo and Lightning systems are leading mechanical thrombectomy platforms for PE and peripheral clot removal. It is a direct competitor to Hēlo with a large installed base, established clinical data, and a global hospital sales force.
  • AngioDynamics: AngioDynamics markets the AlphaVac mechanical thrombectomy system for PE treatment and is the plaintiff in the active patent infringement suit against Endovascular Engineering. It competes head-to-head with Hēlo in the PE thrombectomy category.

Broad incumbents

  • Boston Scientific: Boston Scientific offers the EKOS ultrasound-assisted thrombolysis system for PE and DVT through its peripheral interventions franchise. It is a broad incumbent in interventional cardiology/radiology with the scale and channel access to compete against Hēlo.
  • Stryker: Stryker acquired Inari Medical for $4.9B and now owns the FlowTriever platform, making it the dominant player in mechanical thrombectomy. Stryker's Neurovascular division also competes in adjacent stroke intervention devices, giving it a broad incumbency over the thrombectomy space.
  • Johnson & Johnson (Cerenovus): Cerenovus, J&J's neurovascular and thrombectomy business, offers stent retriever and aspiration technologies for clot removal. It is a broad incumbent with overlapping capabilities in mechanical thrombectomy across peripheral and neurovascular indications.
  • Medtronic: Medtronic's peripheral vascular and cardiac franchises include catheter-based technologies that overlap with Hēlo's addressable market. Its scale, hospital relationships, and ability to bundle across indications make it a powerful indirect competitor and potential acquirer.
  • Abbott: Abbott's vascular and structural heart businesses include catheter-based technologies and would be a relevant broad incumbent comparable in scale and channel access for any thrombectomy platform reaching commercial scale.

Emerging players

  • Walk Vascular: Walk Vascular develops the JETi mechanical thrombectomy system for peripheral and venous applications. It is an emerging niche player with meaningful but partial overlap to Hēlo in the mechanical thrombectomy category.
  • Surmodics: Surmodics has developed catheter-based thrombectomy and drug-delivery coating technologies serving peripheral vascular markets. It is an emerging player with adjacent technology overlap relevant to Endovascular Engineering's catheter platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Endovascular Engineering social profiles

Digital presence

Endovascular Engineering compliance and trust

Trust signal

Compliance1 record

Endovascular Engineering financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Endovascular Engineering leadership team

Management profile

Number of profiles

Profiles12 records

Endovascular Engineering funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Endovascular Engineering M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endovascular Engineering

What does Endovascular Engineering do?

Endovascular Engineering develops and commercializes the Hēlo™ Thrombectomy System, an FDA-cleared mechanical thrombectomy catheter for the treatment of venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis. The catheter-based system combines aspiration with mechanical clot disruption via a self-expanding funnel design, enabling small-profile navigation with large-bore clot engagement in a single-pass procedure.

Is Endovascular Engineering a public or private company?

Endovascular Engineering is a private company. It is classified as venture growth investor backed and is currently operating.

When was Endovascular Engineering founded?

Endovascular Engineering was founded in 2019. It employs 51 to 100 people.

Where is Endovascular Engineering based?

Endovascular Engineering is headquartered in Menlo Park, United States, in the North America region.

How does Endovascular Engineering make money?

One revenue line is on record: Hēlo Thrombectomy System (Hardware Sales).

Who are Endovascular Engineering's main competitors?

Direct peers on record are Inari Medical, Penumbra and AngioDynamics. Broad incumbents are Boston Scientific, Stryker, Johnson & Johnson (Cerenovus), Medtronic and Abbott. Emerging players are Walk Vascular and Surmodics.

Does Endovascular Engineering have an API?

No public API is recorded for Endovascular Engineering.

What industry is Endovascular Engineering in?

Endovascular Engineering's product category is Interventional Cardiology & Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalHelo system offers minimally invasive solution for chronic venous thromboembolismThe Hēlo Thrombectomy System, a device that removes lung blood clots for chronic venous thromboembolism, received FDA clearance. Endovascular Engineering, a U-M startup, is commercializing it, having raised $42 million in Series B and $80 million in Series C financing. The company also reported positive results in its ENGULF trial.Mirage NewsU-M Embolism Treatment Receives FDA ClearanceThe U.S. FDA cleared the Hēlo Thrombectomy System, a device that removes blood clots from vessels using suction and agitation. Developed by University of Michigan engineers and neurosurgeons and commercialized by startup Endovascular Engineering, it targets pulmonary embolism patients. The company has raised $42 million in Series B and $80 million in Series C financing.Medical Device NetworkE2 wins FDA clearances for integrated Hēlo thrombectomy platformEndovascular Engineering (E2) received dual FDA clearances for its Hēlo Return blood-return system and Hēlo thrombectomy platform. The clearance follows the Hēlo platform's December 2025 approval and aims to reduce blood loss during VTE procedures. E2 plans to commercialize the complete solution after its $80m Series C in April.Investing.comAngioDynamics files patent lawsuit against Endovascular Engineering By Investing.comAngioDynamics has filed a patent infringement lawsuit against Endovascular Engineering (E2) in the U.S. District Court for the District of Delaware, alleging that E2's Hēlo Thrombectomy System incorporates features protected by AngioDynamics' registered patents, including proprietary self-expanding funnel technology designed to improve thrombus and emboli removal. The company is seeking damages and equitable relief and stated it intends to vigorously protect its intellectual property rights. Separately, AngioDynamics reported fiscal Q3 2026 earnings that beat expectations with revenue of $78.4 million against a forecast of $76.7 million.Investing.comAngioDynamics files patent lawsuit against Endovascular Engineering By Investing.comAngioDynamics filed a patent infringement lawsuit against Endovascular Engineering (E2) in the U.S. District Court for the District of Delaware, alleging that E2's Hēlo Thrombectomy System incorporates features protected by AngioDynamics' registered patents covering self-expanding funnel technology. The company is seeking damages and equitable relief while stating it intends to vigorously protect its intellectual property rights. Separately, AngioDynamics reported fiscal Q3 2026 earnings that exceeded expectations with EPS of -$0.07 versus a forecast of -$0.09 and revenue of $78.4 million against a forecast of $76.7 million, though its stock declined in pre-market trading following a lowered price target from Canaccord citing margin pressures.citybizEndovascular Engineering Raises $80M to Advance Helo Thrombectomy PlatformEndovascular Engineering, a Menlo Park-based commercial-stage medical technology company, raised $80 million in an oversubscribed Series C funding round to commercialize its Helo thrombectomy platform for pulmonary embolism treatment. The funding was co-led by Gilde Healthcare and Norwest, with participation from multiple global investors including Santé Ventures, S3 Ventures, 415 Capital, Panakès Partners, and M&L Healthcare Investments. The Helo platform features a patented dual-action mechanism combining aspiration with mechanical clot disruption and recently received FDA clearance, positioning the company to expand in the venous thromboembolism care market.VC News DailyEndovascular Engineering Inks $80 Million Series CEndovascular Engineering, a commercial-stage medical technology company focused on treating venous thromboembolism (VTE), announced an oversubscribed $80 million Series C financing round co-led by Gilde Healthcare and Norwest. The round also included participation from existing investors Sante Ventures, 415 Capital, S3 Ventures, Panakes Partners, M&L Healthcare Investments, two existing undisclosed strategic investors, and a new global strategic investor. The funding will support the company's continued commercial expansion and advancement of its VTE treatment technology.Pulse 2.0Endovascular Engineering: $80 Million Raised For Thrombectomy Platform CommercializationEndovascular Engineering, a commercial-stage medical technology company focused on treating venous thromboembolism, has raised $80 million in a Series C financing round co-led by Gilde Healthcare and Norwest to support commercialization of its Hēlo thrombectomy platform. The platform combines aspiration with mechanical clot disruption for treating pulmonary embolism, a leading cause of cardiovascular death. Representatives from Gilde Healthcare and Norwest will join the company's board of directors as part of the financing.MedTech DiveE2 raises $80M to market thrombectomy platformEndovascular Engineering (E2) has raised $80 million in Series C financing to commercialize its Hēlo mechanical thrombectomy system, which received FDA clearance late last year for clot removal from pulmonary arteries and veins. The funding round was co-led by Norwest and Gilde Healthcare, with participation from Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments and undisclosed strategic investors. The financing comes amid heightened M&A activity in the mechanical thrombectomy space, including Boston Scientific's $14.5 billion acquisition of Penumbra and Stryker's $4.9 billion purchase of Inari Medical.Medical Device NetworkE2 raises $80m to advance VTE system’s commercialisationEndovascular Engineering (E2), a California-based medical device company, has raised $80 million in an oversubscribed Series C financing round co-led by Gilde Healthcare and Norwest to advance commercialization of its Hēlo system for venous thromboembolism treatment. The Hēlo system, which received FDA clearance in December 2025, uses a dual-action mechanism combining aspiration with mechanical clot disruption for treating conditions such as pulmonary embolism and deep vein thrombosis. The funding brings E2's total financing to date to $137 million, following a $42 million Series B in February 2025 and a $15 million Series A1 in April 2022.